A Phase I/II, Open-Label, Dose Escalation Followed by Single-Arm Expansion to Assess the Safety and Efficacy of NT219 in Combination with Cetuximab in Patients with Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)

被引：0
|
作者：
Ronen, O. [1 ]
Shickler, M. [2 ]
Reuveni, H. [2 ]
Israel, I. [2 ]
Haviv, I. [2 ]
Waymack, P. J. [2 ]
Cohen, E. [3 ]
机构：
[1] Galilee Med Ctr, Nahariyya, Israel
[2] Kitov Pharma, Tel Aviv, Israel
[3] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2020年 / 106卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
312
引用
收藏
页码：1182 / 1183
页数：2
相关论文
共 50 条
  • [31] Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study
    Ding, Xi
    Zhang, Wei-Jing
    You, Rui
    Zou, Xiong
    Wang, Zhi-Qiang
    Ouyang, Yan-Feng
    Peng, Lan
    Liu, You-Ping
    Duan, Chong-Yang
    Yang, Qi
    Lin, Chao
    Xie, Yu-Long
    Chen, Si-Yuan
    Liu, Yong-Long
    Gu, Chen-Mei
    Xie, Ruo-Qi
    Huang, Pei-Yu
    Hong, Ming-Huang
    Hua, Yi-Jun
    Chen, Ming-Yuan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (14) : 2571 - +
  • [32] EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
    Licitra, Lisa F.
    Haddad, Robert I.
    Even, Caroline
    Tahara, Makoto
    Dvorkin, Mikhail
    Ciuleanu, Tudor-Eliade
    Clement, Paul M.
    Mesia, Ricard
    Kutukova, Svetlana I.
    Zholudeva, Lyubov
    Daste, Amaury
    Caballero, Javier Daroqui
    Keam, Bhumsuk
    Vynnychenko, Ihor
    Lafond, Cedrik
    Shetty, Jagdish
    Morsli, Nassim
    Mann, Helen
    Fayette, Jerome
    Ferris, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [33] Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: A multicenter, open-label, single-arm phase II study
    Srimuninnimit, Vichien
    Sriuranpong, Virote
    Suwanvecho, Suthida
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 (03) : 255 - 260
  • [34] Phase II study of combination cisplatin, docetaxel and erlotinib in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC).
    Kim, E. S.
    Kies, M. S.
    Glisson, B. S.
    Ginsberg, L. E.
    Holsinger, F. C.
    Burke, B. J.
    Truong, M.
    Tsao, A. S.
    Hong, W. K.
    Lippman, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 285S - 285S
  • [35] Mitoxantrone hydrochloride liposome injection for the treatment of Recurrent/Metastatic head and neck squamous cell Carcinoma: A Multicenter, Open-label, Single-arm, phase 1b study
    Yang, Hang
    Sun, Peng
    Wang, Yu
    Wang, Xicheng
    Liu, Yanyan
    Peng, Jiyong
    Zhou, Hui
    Li, Yajun
    Zhang, Hong
    Hu, Jianbing
    Zhang, Bing
    Lin, Shunhuan
    Yang, Chunwei
    Li, Weidong
    Liu, Yanping
    Ji, Meng
    Zhao, Jinghua
    Xue, Jianfei
    Huang, Jiajia
    Li, Zhiming
    ORAL ONCOLOGY, 2025, 162
  • [36] Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
    Takeshita, Naohiro
    Enokida, Tomohiro
    Okano, Susumu
    Fujisawa, Takao
    Wada, Akihisa
    Sato, Masanobu
    Tanaka, Hideki
    Tanaka, Nobukazu
    Onaga, Ryutaro
    Hoshi, Yuta
    Sakashita, Shingo
    Ishii, Genichiro
    Tahara, Makoto
    ORAL ONCOLOGY, 2023, 147
  • [37] Interim analysis of the combination of durvalumab and cetuximab in a phase II trial of patients with recurrent and metastatic head and neck squamous cell carcinoma
    Gulati, Shuchi
    Palackdharry, Sarah
    Weatherford, Layne
    Wilson, Sarah
    Desai, Shireen
    Steele, Aubrey
    Riaz, Kashif
    Takiar, Vinita
    Draper, Trisha
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [38] Preliminary safety and efficacy of toripalimab combined with cetuximab in platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC): A phase Ib/II clinical trial.
    Guo, Ye
    Li, Zhendong
    Chen, Wantao
    Fang, Meiyu
    Liu, Zhigang
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [39] Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial
    Ali A. Mokdad
    Hao Zhu
    Muhammad S. Beg
    Yull Arriaga
    Jonathan E. Dowell
    Amit G. Singal
    Adam C. Yopp
    Targeted Oncology, 2019, 14 : 541 - 550
  • [40] Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial
    Mokdad, Ali A.
    Zhu, Hao
    Beg, Muhammad S.
    Arriaga, Yull
    Dowell, Jonathan E.
    Singal, Amit G.
    Yopp, Adam C.
    TARGETED ONCOLOGY, 2019, 14 (05) : 541 - 550
12345